Citius Oncology (CTOR) Cash from Operations (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Cash from Operations data on file, last reported at 3831618.0 in Q1 2026.

• On a quarterly basis, Cash from Operations changed N/A year-over-year to 3831618.0 in Q1 2026; TTM through Mar 2026 was 11744360.0, a N/A change from a year earlier, with the FY2025 full-year figure at 5492046.0, down 4446.59% from the prior year.
• Cash from Operations for Q1 2026 stood at 3831618.0, up from 7354946.0 in the prior quarter.
• Over the last five years, Cash from Operations for CTOR reached as high as 100256.0 in Q2 2023 and fell as low as 7354946.0 in Q4 2025.
• Historically, Cash from Operations has averaged 1770848.86 across 4 years, with a median of 366106.0 in 2024.
• On a YoY basis, Cash from Operations climbed as much as 13.56% in 2024 and fell as far as 265.17% in 2024.
• Year by year, Cash from Operations stood at 382527.0 in 2023, then rose by 4.29% to 366106.0 in 2024, then plunged by 1908.97% to 7354946.0 in 2025, then surged by 47.9% to 3831618.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 3831618.0 in Q1 2026, 7354946.0 in Q4 2025, and 366106.0 in Q2 2024.